{"count":14,"docs":"https://aiswingx.com/docs","items":[{"accession":"0001628280-26-050134","article_url":null,"attribution":"aiSwingX \u2014 https://aiswingx.com/n/0001628280-26-050134/RevenueFromContractWithCustomerExcludingAssessedTax","change":0.1302279662538144,"cik":1800,"company":"ABBOTT LABORATORIES","concept":{"label":"Revenue","label_en":"Revenue","label_ko":"\ub9e4\ucd9c","period_type":"duration","xbrl_tag":"RevenueFromContractWithCustomerExcludingAssessedTax"},"filed_at":"2026-07-28","filing_index_url":"https://www.sec.gov/Archives/edgar/data/1800/000162828026050134/0001628280-26-050134-index.htm","filing_url":"https://aiswingx.com/f/0001628280-26-050134","form":"10-Q","id":"0001628280-26-050134/RevenueFromContractWithCustomerExcludingAssessedTax","license":"https://aiswingx.com/terms","observations":[{"instant":false,"period_end":"2026-06-30","period_start":"2026-04-01","source_url":"https://www.sec.gov/Archives/edgar/data/1800/000162828026050134/abt-20260630.htm#f-37","unit":"USD","value":12593000000.0,"xbrl_fact_id":"f-37"},{"comparative":true,"instant":false,"period_end":"2025-06-30","period_start":null,"source_url":"https://www.sec.gov/Archives/edgar/data/1800/000162828026050134/abt-20260630.htm#f-38","unit":"USD","value":11142000000.0,"xbrl_fact_id":"f-38"}],"statement":"ABBOTT LABORATORIES (ABT) reported Revenue of USD 12,593,000,000 for the period from 2026-04-01 to 2026-06-30 in its 10-Q (accession 0001628280-26-050134, filed 2026-07-28).","ticker":"ABT","url":"https://aiswingx.com/n/0001628280-26-050134/RevenueFromContractWithCustomerExcludingAssessedTax","verify_url":"https://www.sec.gov/Archives/edgar/data/1800/000162828026050134/abt-20260630.htm#f-37"},{"accession":"0001628280-26-050134","article_url":null,"attribution":"aiSwingX \u2014 https://aiswingx.com/n/0001628280-26-050134/OperatingIncomeLoss","change":-0.17495126705653022,"cik":1800,"company":"ABBOTT LABORATORIES","concept":{"label":"Operating income","label_en":"Operating income","label_ko":"\uc601\uc5c5\uc774\uc775","period_type":"duration","xbrl_tag":"OperatingIncomeLoss"},"filed_at":"2026-07-28","filing_index_url":"https://www.sec.gov/Archives/edgar/data/1800/000162828026050134/0001628280-26-050134-index.htm","filing_url":"https://aiswingx.com/f/0001628280-26-050134","form":"10-Q","id":"0001628280-26-050134/OperatingIncomeLoss","license":"https://aiswingx.com/terms","observations":[{"instant":false,"period_end":"2026-06-30","period_start":"2026-04-01","source_url":"https://www.sec.gov/Archives/edgar/data/1800/000162828026050134/abt-20260630.htm#f-61","unit":"USD","value":1693000000.0,"xbrl_fact_id":"f-61"},{"comparative":true,"instant":false,"period_end":"2025-06-30","period_start":null,"source_url":"https://www.sec.gov/Archives/edgar/data/1800/000162828026050134/abt-20260630.htm#f-62","unit":"USD","value":2052000000.0,"xbrl_fact_id":"f-62"}],"statement":"ABBOTT LABORATORIES (ABT) reported Operating income of USD 1,693,000,000 for the period from 2026-04-01 to 2026-06-30 in its 10-Q (accession 0001628280-26-050134, filed 2026-07-28).","ticker":"ABT","url":"https://aiswingx.com/n/0001628280-26-050134/OperatingIncomeLoss","verify_url":"https://www.sec.gov/Archives/edgar/data/1800/000162828026050134/abt-20260630.htm#f-61"},{"accession":"0001628280-26-050134","article_url":null,"attribution":"aiSwingX \u2014 https://aiswingx.com/n/0001628280-26-050134/NetIncomeLoss","change":-0.47835862844294547,"cik":1800,"company":"ABBOTT LABORATORIES","concept":{"label":"Net income","label_en":"Net income","label_ko":"\uc21c\uc774\uc775","period_type":"duration","xbrl_tag":"NetIncomeLoss"},"filed_at":"2026-07-28","filing_index_url":"https://www.sec.gov/Archives/edgar/data/1800/000162828026050134/0001628280-26-050134-index.htm","filing_url":"https://aiswingx.com/f/0001628280-26-050134","form":"10-Q","id":"0001628280-26-050134/NetIncomeLoss","license":"https://aiswingx.com/terms","observations":[{"instant":false,"period_end":"2026-06-30","period_start":"2026-04-01","source_url":"https://www.sec.gov/Archives/edgar/data/1800/000162828026050134/abt-20260630.htm#f-89","unit":"USD","value":928000000.0,"xbrl_fact_id":"f-89"},{"comparative":true,"instant":false,"period_end":"2025-06-30","period_start":null,"source_url":"https://www.sec.gov/Archives/edgar/data/1800/000162828026050134/abt-20260630.htm#f-90","unit":"USD","value":1779000000.0,"xbrl_fact_id":"f-90"}],"statement":"ABBOTT LABORATORIES (ABT) reported Net income of USD 928,000,000 for the period from 2026-04-01 to 2026-06-30 in its 10-Q (accession 0001628280-26-050134, filed 2026-07-28).","ticker":"ABT","url":"https://aiswingx.com/n/0001628280-26-050134/NetIncomeLoss","verify_url":"https://www.sec.gov/Archives/edgar/data/1800/000162828026050134/abt-20260630.htm#f-89"},{"accession":"0001628280-26-050134","article_url":null,"attribution":"aiSwingX \u2014 https://aiswingx.com/n/0001628280-26-050134/IncomeTaxExpenseBenefit","change":0.6064690026954178,"cik":1800,"company":"ABBOTT LABORATORIES","concept":{"label":"Income tax","label_en":"Income tax","label_ko":"\ubc95\uc778\uc138","period_type":"duration","xbrl_tag":"IncomeTaxExpenseBenefit"},"filed_at":"2026-07-28","filing_index_url":"https://www.sec.gov/Archives/edgar/data/1800/000162828026050134/0001628280-26-050134-index.htm","filing_url":"https://aiswingx.com/f/0001628280-26-050134","form":"10-Q","id":"0001628280-26-050134/IncomeTaxExpenseBenefit","license":"https://aiswingx.com/terms","observations":[{"instant":false,"period_end":"2026-06-30","period_start":"2026-04-01","source_url":"https://www.sec.gov/Archives/edgar/data/1800/000162828026050134/abt-20260630.htm#f-85","unit":"USD","value":596000000.0,"xbrl_fact_id":"f-85"},{"comparative":true,"instant":false,"period_end":"2025-06-30","period_start":null,"source_url":"https://www.sec.gov/Archives/edgar/data/1800/000162828026050134/abt-20260630.htm#f-86","unit":"USD","value":371000000.0,"xbrl_fact_id":"f-86"}],"statement":"ABBOTT LABORATORIES (ABT) reported Income tax of USD 596,000,000 for the period from 2026-04-01 to 2026-06-30 in its 10-Q (accession 0001628280-26-050134, filed 2026-07-28).","ticker":"ABT","url":"https://aiswingx.com/n/0001628280-26-050134/IncomeTaxExpenseBenefit","verify_url":"https://www.sec.gov/Archives/edgar/data/1800/000162828026050134/abt-20260630.htm#f-85"},{"accession":"0001628280-26-050134","article_url":null,"attribution":"aiSwingX \u2014 https://aiswingx.com/n/0001628280-26-050134/ShareBasedCompensation","change":0.12529002320185614,"cik":1800,"company":"ABBOTT LABORATORIES","concept":{"label":"Stock-based compensation","label_en":"Stock-based compensation","label_ko":"\uc8fc\uc2dd\ubcf4\uc0c1","period_type":"duration","xbrl_tag":"ShareBasedCompensation"},"filed_at":"2026-07-28","filing_index_url":"https://www.sec.gov/Archives/edgar/data/1800/000162828026050134/0001628280-26-050134-index.htm","filing_url":"https://aiswingx.com/f/0001628280-26-050134","form":"10-Q","id":"0001628280-26-050134/ShareBasedCompensation","license":"https://aiswingx.com/terms","observations":[{"instant":false,"period_end":"2026-06-30","period_start":"2026-01-01","source_url":"https://www.sec.gov/Archives/edgar/data/1800/000162828026050134/abt-20260630.htm#f-365","unit":"USD","value":485000000.0,"xbrl_fact_id":"f-365"},{"comparative":true,"instant":false,"period_end":"2025-06-30","period_start":null,"source_url":"https://www.sec.gov/Archives/edgar/data/1800/000162828026050134/abt-20260630.htm#f-366","unit":"USD","value":431000000.0,"xbrl_fact_id":"f-366"}],"statement":"ABBOTT LABORATORIES (ABT) reported Stock-based compensation of USD 485,000,000 for the period from 2026-01-01 to 2026-06-30 in its 10-Q (accession 0001628280-26-050134, filed 2026-07-28).","ticker":"ABT","url":"https://aiswingx.com/n/0001628280-26-050134/ShareBasedCompensation","verify_url":"https://www.sec.gov/Archives/edgar/data/1800/000162828026050134/abt-20260630.htm#f-365"},{"accession":"0001628280-26-050134","article_url":null,"attribution":"aiSwingX \u2014 https://aiswingx.com/n/0001628280-26-050134/NetCashProvidedByUsedInOperatingActivities","change":0.09786374133949191,"cik":1800,"company":"ABBOTT LABORATORIES","concept":{"label":"Operating cash flow","label_en":"Operating cash flow","label_ko":"\uc601\uc5c5\ud65c\ub3d9 \ud604\uae08\ud750\ub984","period_type":"duration","xbrl_tag":"NetCashProvidedByUsedInOperatingActivities"},"filed_at":"2026-07-28","filing_index_url":"https://www.sec.gov/Archives/edgar/data/1800/000162828026050134/0001628280-26-050134-index.htm","filing_url":"https://aiswingx.com/f/0001628280-26-050134","form":"10-Q","id":"0001628280-26-050134/NetCashProvidedByUsedInOperatingActivities","license":"https://aiswingx.com/terms","observations":[{"instant":false,"period_end":"2026-06-30","period_start":"2026-01-01","source_url":"https://www.sec.gov/Archives/edgar/data/1800/000162828026050134/abt-20260630.htm#f-373","unit":"USD","value":3803000000.0,"xbrl_fact_id":"f-373"},{"comparative":true,"instant":false,"period_end":"2025-06-30","period_start":null,"source_url":"https://www.sec.gov/Archives/edgar/data/1800/000162828026050134/abt-20260630.htm#f-374","unit":"USD","value":3464000000.0,"xbrl_fact_id":"f-374"}],"statement":"ABBOTT LABORATORIES (ABT) reported Operating cash flow of USD 3,803,000,000 for the period from 2026-01-01 to 2026-06-30 in its 10-Q (accession 0001628280-26-050134, filed 2026-07-28).","ticker":"ABT","url":"https://aiswingx.com/n/0001628280-26-050134/NetCashProvidedByUsedInOperatingActivities","verify_url":"https://www.sec.gov/Archives/edgar/data/1800/000162828026050134/abt-20260630.htm#f-373"},{"accession":"0001628280-26-050134","article_url":null,"attribution":"aiSwingX \u2014 https://aiswingx.com/n/0001628280-26-050134/PaymentsToAcquirePropertyPlantAndEquipment","change":-0.09127789046653144,"cik":1800,"company":"ABBOTT LABORATORIES","concept":{"label":"Capex","label_en":"Capex","label_ko":"\uc124\ube44\ud22c\uc790","period_type":"duration","xbrl_tag":"PaymentsToAcquirePropertyPlantAndEquipment"},"filed_at":"2026-07-28","filing_index_url":"https://www.sec.gov/Archives/edgar/data/1800/000162828026050134/0001628280-26-050134-index.htm","filing_url":"https://aiswingx.com/f/0001628280-26-050134","form":"10-Q","id":"0001628280-26-050134/PaymentsToAcquirePropertyPlantAndEquipment","license":"https://aiswingx.com/terms","observations":[{"instant":false,"period_end":"2026-06-30","period_start":"2026-01-01","source_url":"https://www.sec.gov/Archives/edgar/data/1800/000162828026050134/abt-20260630.htm#f-375","unit":"USD","value":896000000.0,"xbrl_fact_id":"f-375"},{"comparative":true,"instant":false,"period_end":"2025-06-30","period_start":null,"source_url":"https://www.sec.gov/Archives/edgar/data/1800/000162828026050134/abt-20260630.htm#f-376","unit":"USD","value":986000000.0,"xbrl_fact_id":"f-376"}],"statement":"ABBOTT LABORATORIES (ABT) reported Capex of USD 896,000,000 for the period from 2026-01-01 to 2026-06-30 in its 10-Q (accession 0001628280-26-050134, filed 2026-07-28).","ticker":"ABT","url":"https://aiswingx.com/n/0001628280-26-050134/PaymentsToAcquirePropertyPlantAndEquipment","verify_url":"https://www.sec.gov/Archives/edgar/data/1800/000162828026050134/abt-20260630.htm#f-375"},{"accession":"0001628280-26-050134","article_url":null,"attribution":"aiSwingX \u2014 https://aiswingx.com/n/0001628280-26-050134/PaymentsForRepurchaseOfCommonStock","change":3.2832167832167833,"cik":1800,"company":"ABBOTT LABORATORIES","concept":{"label":"Buybacks","label_en":"Buybacks","label_ko":"\uc790\uc0ac\uc8fc \ub9e4\uc785","period_type":"duration","xbrl_tag":"PaymentsForRepurchaseOfCommonStock"},"filed_at":"2026-07-28","filing_index_url":"https://www.sec.gov/Archives/edgar/data/1800/000162828026050134/0001628280-26-050134-index.htm","filing_url":"https://aiswingx.com/f/0001628280-26-050134","form":"10-Q","id":"0001628280-26-050134/PaymentsForRepurchaseOfCommonStock","license":"https://aiswingx.com/terms","observations":[{"instant":false,"period_end":"2026-06-30","period_start":"2026-01-01","source_url":"https://www.sec.gov/Archives/edgar/data/1800/000162828026050134/abt-20260630.htm#f-391","unit":"USD","value":1225000000.0,"xbrl_fact_id":"f-391"},{"comparative":true,"instant":false,"period_end":"2025-06-30","period_start":null,"source_url":"https://www.sec.gov/Archives/edgar/data/1800/000162828026050134/abt-20260630.htm#f-392","unit":"USD","value":286000000.0,"xbrl_fact_id":"f-392"}],"statement":"ABBOTT LABORATORIES (ABT) reported Buybacks of USD 1,225,000,000 for the period from 2026-01-01 to 2026-06-30 in its 10-Q (accession 0001628280-26-050134, filed 2026-07-28).","ticker":"ABT","url":"https://aiswingx.com/n/0001628280-26-050134/PaymentsForRepurchaseOfCommonStock","verify_url":"https://www.sec.gov/Archives/edgar/data/1800/000162828026050134/abt-20260630.htm#f-391"},{"accession":"0001628280-26-050134","article_url":null,"attribution":"aiSwingX \u2014 https://aiswingx.com/n/0001628280-26-050134/AccountsReceivableNetCurrent","change":0.08449993694034556,"cik":1800,"company":"ABBOTT LABORATORIES","concept":{"label":"Accounts receivable","label_en":"Accounts receivable","label_ko":"\ub9e4\ucd9c\ucc44\uad8c","period_type":"instant","xbrl_tag":"AccountsReceivableNetCurrent"},"filed_at":"2026-07-28","filing_index_url":"https://www.sec.gov/Archives/edgar/data/1800/000162828026050134/0001628280-26-050134-index.htm","filing_url":"https://aiswingx.com/f/0001628280-26-050134","form":"10-Q","id":"0001628280-26-050134/AccountsReceivableNetCurrent","license":"https://aiswingx.com/terms","observations":[{"instant":true,"period_end":"2026-06-30","period_start":null,"source_url":"https://www.sec.gov/Archives/edgar/data/1800/000162828026050134/abt-20260630.htm#f-167","unit":"USD","value":8599000000.0,"xbrl_fact_id":"f-167"},{"comparative":true,"instant":true,"period_end":"2025-12-31","period_start":null,"source_url":"https://www.sec.gov/Archives/edgar/data/1800/000162828026050134/abt-20260630.htm#f-168","unit":"USD","value":7929000000.0,"xbrl_fact_id":"f-168"}],"statement":"ABBOTT LABORATORIES (ABT) reported Accounts receivable of USD 8,599,000,000 as of 2026-06-30 in its 10-Q (accession 0001628280-26-050134, filed 2026-07-28).","ticker":"ABT","url":"https://aiswingx.com/n/0001628280-26-050134/AccountsReceivableNetCurrent","verify_url":"https://www.sec.gov/Archives/edgar/data/1800/000162828026050134/abt-20260630.htm#f-167"},{"accession":"0001628280-26-050134","article_url":null,"attribution":"aiSwingX \u2014 https://aiswingx.com/n/0001628280-26-050134/InventoryNet","change":0.12746609124537608,"cik":1800,"company":"ABBOTT LABORATORIES","concept":{"label":"Inventory","label_en":"Inventory","label_ko":"\uc7ac\uace0","period_type":"instant","xbrl_tag":"InventoryNet"},"filed_at":"2026-07-28","filing_index_url":"https://www.sec.gov/Archives/edgar/data/1800/000162828026050134/0001628280-26-050134-index.htm","filing_url":"https://aiswingx.com/f/0001628280-26-050134","form":"10-Q","id":"0001628280-26-050134/InventoryNet","license":"https://aiswingx.com/terms","observations":[{"instant":true,"period_end":"2026-06-30","period_start":null,"source_url":"https://www.sec.gov/Archives/edgar/data/1800/000162828026050134/abt-20260630.htm#f-175","unit":"USD","value":7315000000.0,"xbrl_fact_id":"f-175"},{"comparative":true,"instant":true,"period_end":"2025-12-31","period_start":null,"source_url":"https://www.sec.gov/Archives/edgar/data/1800/000162828026050134/abt-20260630.htm#f-176","unit":"USD","value":6488000000.0,"xbrl_fact_id":"f-176"}],"statement":"ABBOTT LABORATORIES (ABT) reported Inventory of USD 7,315,000,000 as of 2026-06-30 in its 10-Q (accession 0001628280-26-050134, filed 2026-07-28).","ticker":"ABT","url":"https://aiswingx.com/n/0001628280-26-050134/InventoryNet","verify_url":"https://www.sec.gov/Archives/edgar/data/1800/000162828026050134/abt-20260630.htm#f-175"},{"accession":"0001628280-26-050134","article_url":null,"attribution":"aiSwingX \u2014 https://aiswingx.com/n/0001628280-26-050134/CashAndCashEquivalentsAtCarryingValue","change":-0.4010795587890167,"cik":1800,"company":"ABBOTT LABORATORIES","concept":{"label":"Cash","label_en":"Cash","label_ko":"\ud604\uae08","period_type":"instant","xbrl_tag":"CashAndCashEquivalentsAtCarryingValue"},"filed_at":"2026-07-28","filing_index_url":"https://www.sec.gov/Archives/edgar/data/1800/000162828026050134/0001628280-26-050134-index.htm","filing_url":"https://aiswingx.com/f/0001628280-26-050134","form":"10-Q","id":"0001628280-26-050134/CashAndCashEquivalentsAtCarryingValue","license":"https://aiswingx.com/terms","observations":[{"instant":true,"period_end":"2026-06-30","period_start":null,"source_url":"https://www.sec.gov/Archives/edgar/data/1800/000162828026050134/abt-20260630.htm#f-161","unit":"USD","value":5104000000.0,"xbrl_fact_id":"f-161"},{"comparative":true,"instant":true,"period_end":"2025-12-31","period_start":null,"source_url":"https://www.sec.gov/Archives/edgar/data/1800/000162828026050134/abt-20260630.htm#f-162","unit":"USD","value":8522000000.0,"xbrl_fact_id":"f-162"}],"statement":"ABBOTT LABORATORIES (ABT) reported Cash of USD 5,104,000,000 as of 2026-06-30 in its 10-Q (accession 0001628280-26-050134, filed 2026-07-28).","ticker":"ABT","url":"https://aiswingx.com/n/0001628280-26-050134/CashAndCashEquivalentsAtCarryingValue","verify_url":"https://www.sec.gov/Archives/edgar/data/1800/000162828026050134/abt-20260630.htm#f-161"},{"accession":"0001628280-26-050134","article_url":null,"attribution":"aiSwingX \u2014 https://aiswingx.com/n/0001628280-26-050134/LongTermDebtNoncurrent","change":1.991410670978173,"cik":1800,"company":"ABBOTT LABORATORIES","concept":{"label":"Long-term debt","label_en":"Long-term debt","label_ko":"\uc7a5\uae30\ubd80\ucc44","period_type":"instant","xbrl_tag":"LongTermDebtNoncurrent"},"filed_at":"2026-07-28","filing_index_url":"https://www.sec.gov/Archives/edgar/data/1800/000162828026050134/0001628280-26-050134-index.htm","filing_url":"https://aiswingx.com/f/0001628280-26-050134","form":"10-Q","id":"0001628280-26-050134/LongTermDebtNoncurrent","license":"https://aiswingx.com/terms","observations":[{"instant":true,"period_end":"2026-06-30","period_start":null,"source_url":"https://www.sec.gov/Archives/edgar/data/1800/000162828026050134/abt-20260630.htm#f-211","unit":"USD","value":29603000000.0,"xbrl_fact_id":"f-211"},{"comparative":true,"instant":true,"period_end":"2025-12-31","period_start":null,"source_url":"https://www.sec.gov/Archives/edgar/data/1800/000162828026050134/abt-20260630.htm#f-212","unit":"USD","value":9896000000.0,"xbrl_fact_id":"f-212"}],"statement":"ABBOTT LABORATORIES (ABT) reported Long-term debt of USD 29,603,000,000 as of 2026-06-30 in its 10-Q (accession 0001628280-26-050134, filed 2026-07-28).","ticker":"ABT","url":"https://aiswingx.com/n/0001628280-26-050134/LongTermDebtNoncurrent","verify_url":"https://www.sec.gov/Archives/edgar/data/1800/000162828026050134/abt-20260630.htm#f-211"},{"accession":"0001628280-26-050134","article_url":null,"attribution":"aiSwingX \u2014 https://aiswingx.com/n/0001628280-26-050134/Assets","change":0.2594997289910394,"cik":1800,"company":"ABBOTT LABORATORIES","concept":{"label":"Total assets","label_en":"Total assets","label_ko":"\ucd1d\uc790\uc0b0","period_type":"instant","xbrl_tag":"Assets"},"filed_at":"2026-07-28","filing_index_url":"https://www.sec.gov/Archives/edgar/data/1800/000162828026050134/0001628280-26-050134-index.htm","filing_url":"https://aiswingx.com/f/0001628280-26-050134","form":"10-Q","id":"0001628280-26-050134/Assets","license":"https://aiswingx.com/terms","observations":[{"instant":true,"period_end":"2026-06-30","period_start":null,"source_url":"https://www.sec.gov/Archives/edgar/data/1800/000162828026050134/abt-20260630.htm#f-195","unit":"USD","value":109215000000.0,"xbrl_fact_id":"f-195"},{"comparative":true,"instant":true,"period_end":"2025-12-31","period_start":null,"source_url":"https://www.sec.gov/Archives/edgar/data/1800/000162828026050134/abt-20260630.htm#f-196","unit":"USD","value":86713000000.0,"xbrl_fact_id":"f-196"}],"statement":"ABBOTT LABORATORIES (ABT) reported Total assets of USD 109,215,000,000 as of 2026-06-30 in its 10-Q (accession 0001628280-26-050134, filed 2026-07-28).","ticker":"ABT","url":"https://aiswingx.com/n/0001628280-26-050134/Assets","verify_url":"https://www.sec.gov/Archives/edgar/data/1800/000162828026050134/abt-20260630.htm#f-195"},{"accession":"0001628280-26-050134","article_url":null,"attribution":"aiSwingX \u2014 https://aiswingx.com/n/0001628280-26-050134/StockholdersEquity","change":-0.01956646844427393,"cik":1800,"company":"ABBOTT LABORATORIES","concept":{"label":"Total equity","label_en":"Total equity","label_ko":"\uc790\uae30\uc790\ubcf8","period_type":"instant","xbrl_tag":"StockholdersEquity"},"filed_at":"2026-07-28","filing_index_url":"https://www.sec.gov/Archives/edgar/data/1800/000162828026050134/0001628280-26-050134-index.htm","filing_url":"https://aiswingx.com/f/0001628280-26-050134","form":"10-Q","id":"0001628280-26-050134/StockholdersEquity","license":"https://aiswingx.com/terms","observations":[{"instant":true,"period_end":"2026-06-30","period_start":null,"source_url":"https://www.sec.gov/Archives/edgar/data/1800/000162828026050134/abt-20260630.htm#f-239","unit":"USD","value":51110000000.0,"xbrl_fact_id":"f-239"},{"comparative":true,"instant":true,"period_end":"2025-12-31","period_start":null,"source_url":"https://www.sec.gov/Archives/edgar/data/1800/000162828026050134/abt-20260630.htm#f-240","unit":"USD","value":52130000000.0,"xbrl_fact_id":"f-240"}],"statement":"ABBOTT LABORATORIES (ABT) reported Total equity of USD 51,110,000,000 as of 2026-06-30 in its 10-Q (accession 0001628280-26-050134, filed 2026-07-28).","ticker":"ABT","url":"https://aiswingx.com/n/0001628280-26-050134/StockholdersEquity","verify_url":"https://www.sec.gov/Archives/edgar/data/1800/000162828026050134/abt-20260630.htm#f-239"}],"limit":100,"note":"Inline XBRL facts as filed with the SEC, each with a permanent citation URL and a deep link to the figure in the filing document.","offset":0,"total":14}